Skip to content
ContentLora

    Tip: press / anywhere to search.

    Explainer

    How CAR-T cell therapy works

    CAR-T therapy collects a patient's T cells, engineers them to carry a chimeric antigen receptor that recognises cancer, grows them to hundreds of millions and infuses them back, a process of about 3 to 5 weeks.[1] It has transformed some blood cancers since the first approval in 2017, but solid tumours remain much harder.[2][3]

    Editor reviewedStrict sourcingUpdated Cancer immunotherapyHealth and medicineLife sciences

    CAR-T therapy is a living drug: a patient’s own T cells, genetically re-aimed at their cancer.[1] It is one of two main forms of T-cell transfer therapy, alongside tumour-infiltrating lymphocyte (TIL) therapy.[4] For the products, approvals and safety record, see car-t-cell-therapy.

    The four steps

    1. Collect. Blood is taken and the T cells are separated out.[1]
    2. Engineer. In a lab, the T cells are given a gene for a new receptor, a CAR, that recognises a mark on the cancer.[1]
    3. Expand. The cells are grown until there are hundreds of millions.[1]
    4. Infuse. They go back to the patient as a single infusion. The whole process takes about 3 to 5 weeks.[1]

    Autologous manufacturing runs leukapheresis, genetic modification to express a chimeric antigen receptor, ex vivo expansion to hundreds of millions of cells, and a single infusion, with a vein-to-vein time NCI puts at 3 to 5 weeks.[1] Approved products target CD19 or BCMA on B-cell and plasma-cell cancers.[5] Two alternatives aim to remove the bespoke manufacturing step: allogeneic products made from healthy donors’ cells, and in vivo CAR-T, which uses a vector to create CAR-T cells inside the body.[6][7]

    What it can do

    The first CAR-T therapy, Kymriah, was approved in the US in 2017 for children and young adults with a type of leukaemia. Within three months, 83% went into remission.[2] In December 2025 a CAR-T therapy was approved for marginal zone lymphoma, where 95.5% of 66 patients responded.[8]

    Tisagenlecleucel’s 2017 approval in relapsed or refractory paediatric and young-adult B-ALL rested on an 83% overall remission rate within three months.[2] Indications have since broadened, for example lisocabtagene maraleucel in marginal zone lymphoma (December 2025; 95.5% response rate, n=66) and obecabtagene autoleucel in adult B-ALL (November 2024).[8][9]

    Side effects and safety rules

    When CAR-T cells attack, they release chemical signals that can cause cytokine release syndrome: very high fevers and sharp drops in blood pressure. Some patients get neurological symptoms such as confusion.[10] Rarely, patients have later developed a new T-cell cancer, so the FDA says they should be monitored for life.[5]

    Cytokine release syndrome and ICANS are the defining acute toxicities, managed with tocilizumab, steroids or anakinra.[10] In April 2024 the FDA added a class boxed warning for T-cell malignancies, including CAR-positive tumours, with life-long monitoring.[5] In June 2025 it removed REMS programmes for autologous products, halving the required stay near a treatment centre to two weeks.[11]

    Why solid tumours are harder

    Blood cancers carry clear target marks. Solid tumours often do not, they build a protective environment that weakens T cells, and their cells vary a lot.[3] In June 2026 China approved the first CAR-T therapy for a solid tumour, a type of stomach cancer.[12]

    NCI frames the solid-tumour problem as antigen scarcity, microenvironmental immunosuppression and heterogeneity.[3] In a randomised trial in claudin-18.2-positive gastric cancer, the CAR-T therapy satri-cel improved median PFS from 1.77 to 3.25 months.[13] See the solid-tumour debate page for what this does and does not show.

    Questions readers ask

    How long does it take to make CAR-T cells?

    NCI puts the whole process, from collecting T cells to infusing the engineered cells, at about 3 to 5 weeks.[1]

    What are the main side effects of CAR-T?

    Cytokine release syndrome, which can cause dangerously high fevers and steep drops in blood pressure, and neurotoxicity (ICANS), with symptoms such as confusion and impaired speech. The FDA also requires a boxed warning about secondary T-cell cancers.[10][5]

    Why is CAR-T harder in solid tumours?

    NCI cites a lack of suitable surface targets, an immunosuppressive tumour environment and variation between and within tumours.[3]

    When was the first CAR-T therapy approved?

    The FDA approved tisagenlecleucel (Kymriah) on 30 August 2017 for children and young adults with B-cell acute lymphoblastic leukaemia.[2]

    Sources

    Each numbered claim is a statement we checked against the sources listed with it. Status shows how well established it is.

    1. [1]

      CAR T-cell therapy collects a patient's T cells, genetically engineers them to make chimeric antigen receptors, grows them to hundreds of millions and returns them as a single infusion, a process NCI puts at about 3 to 5 weeks. confirmedas of 2025-02-26

    2. [2]

      On 30 August 2017 the FDA approved the first CAR T-cell therapy, tisagenlecleucel (Kymriah), for children and young adults with B-cell acute lymphoblastic leukaemia; the overall remission rate within three months was 83%. confirmedas of 2017-08-30

    3. [3]

      NCI identifies three obstacles for CAR T cells in solid tumours: few suitable surface antigens, an immunosuppressive tumour environment, and molecular variation between and within tumours. confirmedas of 2025-02-26

    4. [4]

      NCI describes two main types of T-cell transfer therapy: tumour-infiltrating lymphocyte (TIL) therapy and CAR T-cell therapy. confirmedas of 2026-10-10

    5. [5]

      In April 2024 the FDA required a boxed warning on six approved BCMA- or CD19-directed autologous CAR-T products for the risk of T-cell malignancies, and said patients should be monitored life-long for secondary cancers. confirmedas of 2024-04-18

    6. [6]

      Researchers are developing off-the-shelf (allogeneic) CAR-T products made from healthy donors' T cells rather than each patient's own cells. confirmedas of 2025-02-26

    7. [7]

      ESO-T01 is a lentiviral vector given as a single intravenous infusion that generates anti-BCMA CAR-T cells inside the body, without leukapheresis, ex vivo manufacturing or lymphodepleting chemotherapy. confirmedas of 2026-04-01

    8. [8]

      On 4 December 2025 the FDA approved lisocabtagene maraleucel (Breyanzi) as the first CAR T-cell therapy for marginal zone lymphoma; 95.5% of 66 treated patients responded. confirmedas of 2025-12-04

    9. [9]

      On 8 November 2024 the FDA approved obecabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia. confirmedas of 2024-11-08

    10. [10]

      The main acute CAR-T toxicities are cytokine release syndrome, which can cause dangerously high fevers and steep drops in blood pressure, and neurotoxicity (ICANS), with symptoms such as confusion and impaired speech. confirmedas of 2025-02-26

    11. [11]

      In June 2025 the FDA removed the REMS safety programmes for approved autologous CAR-T therapies, cutting the recommended stay near a treatment centre from four weeks to two and the driving restriction from eight weeks to two. confirmedas of 2025-10-02

    12. [12]

      In June 2026 China's NMPA approved CARsgen's satri-cel for claudin-18.2-positive, HER2-negative advanced gastric or gastro-oesophageal junction cancer, described as the first CAR T-cell therapy approved for a solid tumour. confirmedas of 2026-09-01

    13. [13]

      In a randomised phase 2 trial of 156 patients with previously treated claudin-18.2-positive gastric or gastro-oesophageal junction cancer, the CAR-T therapy satri-cel extended median progression-free survival to 3.25 months versus 1.77 months with physician's choice (hazard ratio 0.37). confirmedas of 2025-06-01

    Revision history (1)
    1. Page created.

    Created Oct 10, 2026. Last reviewed by an editor on Oct 10, 2026. Next scheduled review: Jan 10, 2027.

    Cite this page

    "How CAR-T cell therapy works." ContentLora, updated Oct 10, 2026. https://contentlora.com/explain/how-car-t-cell-therapy-works

    Spotted an error? Suggest a correction or emailcorrections@contentlora.com.

    Keep exploring

    ☰ Contents